27.90
price up icon13.09%   3.23
pre-market  Pre-mercato:  27.92   0.02   +0.07%
loading
Precedente Chiudi:
$24.67
Aprire:
$25.93
Volume 24 ore:
7.35M
Relative Volume:
1.98
Capitalizzazione di mercato:
$17.43B
Reddito:
$956.00K
Utile/perdita netta:
$-221.32M
Rapporto P/E:
-87.19
EPS:
-0.32
Flusso di cassa netto:
$-142.25M
1 W Prestazione:
+18.90%
1M Prestazione:
+36.36%
6M Prestazione:
+46.92%
1 anno Prestazione:
+587.19%
Intervallo 1D:
Value
$25.81
$29.99
Intervallo di 1 settimana:
Value
$22.84
$29.99
Portata 52W:
Value
$2.10
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Nome
Summit Therapeutics Inc
Name
Telefono
305-203-2034
Name
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Name
Dipendente
159
Name
Cinguettio
@summitplc
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
SMMT's Discussions on Twitter

Confronta SMMT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SMMT
Summit Therapeutics Inc
27.90 17.43B 956.00K -221.32M -142.25M -0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-26 Aggiornamento Citigroup Neutral → Buy
2025-03-21 Iniziato Cantor Fitzgerald Overweight
2025-03-12 Iniziato Evercore ISI Outperform
2025-02-28 Iniziato Goldman Buy
2025-01-08 Iniziato Truist Buy
2024-12-11 Iniziato Wells Fargo Overweight
2024-12-06 Iniziato Jefferies Buy
2024-11-04 Iniziato JMP Securities Mkt Outperform
2024-09-27 Downgrade Citigroup Buy → Neutral
2024-08-12 Iniziato H.C. Wainwright Buy
2024-05-07 Iniziato Citigroup Buy
2024-03-26 Iniziato Stifel Buy
2018-06-28 Downgrade Janney Buy → Neutral
2018-05-02 Iniziato Janney Buy
2018-04-12 Reiterato Needham Buy
2018-02-13 Iniziato BTIG Research Buy
2018-01-04 Iniziato SunTrust Buy
2017-12-01 Ripresa H.C. Wainwright Buy
2016-11-16 Reiterato RBC Capital Mkts Outperform
2016-10-05 Reiterato Needham Buy
2016-09-16 Iniziato H.C. Wainwright Buy
2015-03-30 Iniziato Needham Buy
2015-03-30 Iniziato Oppenheimer Outperform
Mostra tutto

Summit Therapeutics Inc Borsa (SMMT) Ultime notizie

pulisher
May 04, 2025

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga

May 04, 2025
pulisher
May 04, 2025

Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN

May 04, 2025
pulisher
May 04, 2025

Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey

May 04, 2025
pulisher
May 02, 2025

Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025
pulisher
May 02, 2025

This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 02, 2025
pulisher
May 02, 2025

Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire

May 01, 2025
pulisher
May 01, 2025

Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance

Apr 30, 2025
pulisher
Apr 28, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market Overreaction | SMMT Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN

Apr 28, 2025
pulisher
Apr 27, 2025

Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus

Apr 27, 2025
pulisher
Apr 26, 2025

Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı

Apr 26, 2025
pulisher
Apr 26, 2025

Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus

Apr 26, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize

Apr 25, 2025
pulisher
Apr 25, 2025

Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics (SMMT) Sees Stock Drop Despite Positive Drug - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Summit Therapeutics Gets Approval From China's Health Authority for Second Use of Ivonescimab - marketscreener.com

Apr 25, 2025

Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$32.89
price up icon 1.26%
$21.48
price up icon 2.63%
$72.30
price down icon 0.47%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Capitalizzazione:     |  Volume (24 ore):